Search research articles
Contact Us
Filters
Showing results (191-200 of 282) with videos related to
Page
of 29
Sort By:
ERJ Open Research
|
March 15, 2021
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis
MeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
The European Respiratory Journal
|
September 7, 2019
Misinterpretation of time-to-first event curves can lead to inappropriate treatment
Benjamin Hartley, Gerard J Criner, Mark T Dransfield, et al.
Respiratory Research
|
February 2, 2023
X chromosome associations with chronic obstructive pulmonary disease and related phenotypes: an X chromosome-wide association study
Lystra P Hayden, Brian D Hobbs, Robert Busch, et al.
Advances in Therapy
|
July 11, 2020
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
Maggie Tabberer, C Elaine Jones, Sally Kilbride, et al.
The European Respiratory Journal
|
June 15, 2013
Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort
Alvar Agusti, Lisa D Edwards, Bartolomé Celli, et al.
Science Advances
|
October 22, 2020
The structural basis for Z α<sub>1</sub>-antitrypsin polymerization in the liver
Sarah V Faull, Emma L K Elliston, Bibek Gooptu, et al.
The Biochemical Journal
|
July 14, 2016
An antibody that prevents serpin polymerisation acts by inducing a novel allosteric behaviour
Neda Motamedi-Shad, Alistair M Jagger, Maximilian Liedtke, et al.
The International Journal of Biochemistry & Cell Biology
|
December 3, 2014
Characterising the association of latency with α(1)-antitrypsin polymerisation using a novel monoclonal antibody
Lu Tan, Juan Perez, Marianna Mela, et al.
COPD
|
May 17, 2014
Evaluating the role of inflammation in chronic airways disease: the ERICA study
Divya Mohan, Nichola S Gale, Carmel M McEniery, et al.
Respiratory Research
|
June 7, 2020
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
Nicola C Day, Subramanya Kumar, Gerard Criner, et al.
Page
of 29
Search research articles
Search
Showing results (191-200 of 282) with videos related to
Sort By:
Page
of 29
ERJ Open Research
|
March 15, 2021
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis
MeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
The European Respiratory Journal
|
September 7, 2019
Misinterpretation of time-to-first event curves can lead to inappropriate treatment
Benjamin Hartley, Gerard J Criner, Mark T Dransfield, et al.
Respiratory Research
|
February 2, 2023
X chromosome associations with chronic obstructive pulmonary disease and related phenotypes: an X chromosome-wide association study
Lystra P Hayden, Brian D Hobbs, Robert Busch, et al.
Advances in Therapy
|
July 11, 2020
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
Maggie Tabberer, C Elaine Jones, Sally Kilbride, et al.
The European Respiratory Journal
|
June 15, 2013
Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort
Alvar Agusti, Lisa D Edwards, Bartolomé Celli, et al.
Science Advances
|
October 22, 2020
The structural basis for Z α<sub>1</sub>-antitrypsin polymerization in the liver
Sarah V Faull, Emma L K Elliston, Bibek Gooptu, et al.
The Biochemical Journal
|
July 14, 2016
An antibody that prevents serpin polymerisation acts by inducing a novel allosteric behaviour
Neda Motamedi-Shad, Alistair M Jagger, Maximilian Liedtke, et al.
The International Journal of Biochemistry & Cell Biology
|
December 3, 2014
Characterising the association of latency with α(1)-antitrypsin polymerisation using a novel monoclonal antibody
Lu Tan, Juan Perez, Marianna Mela, et al.
COPD
|
May 17, 2014
Evaluating the role of inflammation in chronic airways disease: the ERICA study
Divya Mohan, Nichola S Gale, Carmel M McEniery, et al.
Respiratory Research
|
June 7, 2020
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
Nicola C Day, Subramanya Kumar, Gerard Criner, et al.
Page
of 29